


PHARMACEUTICAL 2022



OptiNose Inc. Rank 308 of 475





PHARMACEUTICAL 2022



OptiNose Inc. Rank 308 of 475

The relative strengths and weaknesses of OptiNose Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OptiNose Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 117% points. The greatest weakness of OptiNose Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is -202%, being 74% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	160,379
Cost of Goods Sold	9,151
Intangible Assets	0
Liabilities, Current	59,235
Liabilities, Non-Current	128,608
Other Assets	4,345
Other Compr. Net Income	4.0
Other Expenses	15,973
Other Liabilities	0
Other Net Income	52
Property and Equipment	1,347
Research and Development	25,318
Revenues	74,727
Selling, General and Administrative Expense	106,633

Output Variable	Value in 1000 USD
Assets	166,071
Liabilities	187,843
Expenses	157,075
Stockholders Equity	-21,772
Net Income	-82,296
Comprehensive Net Income	-82,294
Economic Capital Ratio	-202%

